Assess the Absorption, Distribution, Metabolism and Excretion of AZD7325 After Intravenous and Oral Administration
- Registration Number
- NCT00940641
- Lead Sponsor
- AstraZeneca
- Brief Summary
The purpose of this study is to evaluate the absorption, distribution, metabolism and excretion of AZD7325 after intravenous and 14C labeled oral dose
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- SUSPENDED
- Sex
- Male
- Target Recruitment
- 8
Inclusion Criteria
- Healthy subjects Day 1
- Body Mass Index (BMI) > 18 and < 30kg/m2
Exclusion Criteria
- Clinically relevant disease and abnormalities (past or present) which in the opinion of the investigator, may either put the subject at risk to participate in this study or may influence the results of the study or the subject's ability to participate in the study
- Use of prescription medication within 14 days of the first dose of the investigational product
- Blood loss in excess of 200 mL within 30 days of Day-1 in excess of 500 mL within 90 days of Day-1 or in excess of 1350 mL within 1 year of Day-1 or donation of blood products within 14 days of Day -1
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description 1 AZD7325 IV dose of AZD7325 2 AZD7325 14C oral dose of AZD7325
- Primary Outcome Measures
Name Time Method To assess absorption, distribution, metabolism and excretion of AZD7325 after IV dose and 14C oral dose administration Daily
- Secondary Outcome Measures
Name Time Method To evaluate safety and tolerability after a single oral administration of [14C] AZD7325 and after a single intravenous administration of non radio-labelled AZD7325 Daily
Trial Locations
- Locations (1)
Research Site
🇬🇧Alderley Park, United Kingdom